Abstract: A method and medicant for the inhibition of activation of the nuclear transcription NF-.kappa.B comprising administering an effective amount of a compound of the formula: ##STR1## where R=ethylene, R'=C.sub.4 to C.sub.14 straight chain or branched alkyl, x is greater than 1, and y=8 to 18 is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF is provided.

Abstract: A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. Also, a method and medicament for mucociliary clearance, inhibition of cytokine production, and inhibition of interleukin-8 production in cystic fibrosis patients. The method involves administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.

Abstract: A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O-desulfated heparin.

Abstract: A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O-desulfated heparin.

Abstract: A disposable splint for holding a broken leg of a patient in traction is made of layered, corrugated cardboard or the like and has central, side and end panels. The panels at a proximal end are foldable to form an open end to engage the ischia of the patient. The side panels are foldable to be perpendicular to the central panel. At the distal end, a panel is foldable to form a foot plate having a central opening through which a tension strap can be passed from the patient's ankle to a tension rod. On the outer surface of the foot plate, laterally extending flaps are foldable to form supports with central slots to receive the tension rod. When applied to a patient, the leg is placed in traction manually, the splint is applied and the tension strap and rod are used to maintain the leg in traction so that the patient can be safely transported for further medical care.

Abstract: The present invention relates to use of alkylaryl polyether alcohol polymers as antioxidants to suppress certain oxidant chemical reactions that cause tissue injury and disease in mammals. Disclosed is a method of inhibiting oxidants using alkylaryl polyether alcohol polymers. More particularly, disclosed is a method for the treatment of mammalian disease entities related to overproduction of partially reduced oxygen species comprising administering to a mammal a treatment effective amount of an alkylaryl polyether alcohol polymer. The mammalian disease entities include, but are not limited to, myocardial infarction, stroke, adult respiratory distress syndrome, oxygen toxicity of the lung, lung injury from asbestos, Parkinson's disease, thermal and solar burns of the skin, and injury to the gastrointestinal tract from nonsteroidal anti-inflammatory agents.

Abstract: A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.

Abstract: The disclosure relates to compounds of the formula ##STR1## and pharmaceutically acceptable addition salts thereof wherein X represents a single, direct bond or a substituted or unsubstituted alkylene chain containing 1 to 4 carbon atoms, wherein R.sub.5 is a lower alkyl group, wherein R.sub.6 is either hydrogen or methyl, wherein Am is selected from the class consisting of amino, lower mono and dialkylamino, piperidino, piperazino, N-lower alkyl piperazino, pyrrolidino, and morpholino groups, wherein Y.sub.1 and Y.sub.2 are identical and are hydrogen, a halogen, methyl or ethyl048505325 and n is an integer in the range of 1-5.

Abstract: The disclosure relates to compounds of the formula ##STR1## and pharmaceutically acceptable addition salts thereof wherein X represents a substituted or unsubstituted alkylene chain containing 1 to 4 carbon atoms, wherein R.sub.5 is a lower alkyl group, wherein R.sub.6 is either hydrogen or methyl, R.sub.9 is hydrogen or lower alkyl, wherein Am is selected from the class consisting of amino, lower mono and dialkylamino, piperidino, piperazino, N-lower alkyl piperazino, pyrrolidino, and morpholino groups, wherein Y.sub.1 and Y.sub.2 are identical and are hydrogen, halogen, methyl or ethyl and n is an integer in the range of 1-5.

Abstract: The disclosure relates to compounds of the formula ##STR1## and pharmaceutically acceptable addition salts thereof wherein R.sub.1 represents hydrogen, R.sub.1 represents a group having the formula --OR.sub.2 in which R.sub.2 is a lower alkyl group or an aryl group, or R.sub.1 represents a group having the formula ##STR2## in which R.sub.3 is hydrogen, a lower alkyl group, or an aryl group, wherein R.sub.4 is a lower alkyl group containing 1 to 6 carbon atoms, wherein R.sub.5 is either hydrogen or methyl, wherein NR.sub.6 is a group selected from the class consisting of amino, lower mono and dialkylamino, piperidino, pyrrolidino, and morpholino groups and wherein Y.sub.1 and Y.sub.2 are identical and are hydrogen or a halogen. Compounds in accordance with the invention are useful as vasodilators and as antiarrythmic agents.

Abstract: Methods are disclosed for employing diphenylhalonium ion to elicit sodium nitroprusside-like effects in vivo, and to enhance cardiac contractility.